Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Metastatic Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04639986
What this trial is testing

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Who this might be right for
Metastatic Breast Cancer
Gilead Sciences 331
Large-scale testing (Phase 3)Ended earlyNCT04740918
What this trial is testing

Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 96
Not applicableLooking for participantsNCT06358625
What this trial is testing

Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Center Eugene Marquis 120
Testing effectiveness (Phase 2)UnknownNCT00687648
What this trial is testing

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
National Cancer Centre, Singapore 70
Testing effectiveness (Phase 2)Ended earlyNCT01658358
What this trial is testing

ErbB2 Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
China Medical University Hospital 15
Testing effectiveness (Phase 2)UnknownNCT04095390
What this trial is testing

A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2-positive Breast Cancer
Jinming Yu 60
Not applicableUnknownNCT04609540
What this trial is testing

Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Shandong Cancer Hospital and Institute 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07177950
What this trial is testing

A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases

Who this might be right for
Breast CancerBrain MetastasesLeptomeningeal Metastasis
Peking University Cancer Hospital & Institute 51
Testing effectiveness (Phase 2)Looking for participantsNCT07007559
What this trial is testing

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer, Metastatic
ALX Oncology Inc. 120
Testing effectiveness (Phase 2)Study completedNCT02048059
What this trial is testing

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Who this might be right for
Breast CancerBrain Metastases
Angiochem Inc 72
Not applicableUnknownNCT05764941
What this trial is testing

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
The First Affiliated Hospital with Nanjing Medical University 100
Large-scale testing (Phase 3)Active Not RecruitingNCT04305496
What this trial is testing

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 818
Testing effectiveness (Phase 2)Active Not RecruitingNCT06957379
What this trial is testing

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Who this might be right for
HR+/HER2- Advanced/Metastatic Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 78
Early research (Phase 1)Ended earlyNCT06714617
What this trial is testing

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Who this might be right for
Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast Carcinoma+11 more
SystImmune Inc. 3
Not applicableUnknownNCT06344780
What this trial is testing

Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 200
Early research (Phase 1)Active Not RecruitingNCT05509790
What this trial is testing

LY3484356 in Chinese Participants With Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Eli Lilly and Company 17
Large-scale testing (Phase 3)Looking for participantsNCT04646759
What this trial is testing

Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 516
Testing effectiveness (Phase 2)Study completedNCT00077376
What this trial is testing

Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more
National Cancer Institute (NCI) 61
Large-scale testing (Phase 3)Study completedNCT00003440
What this trial is testing

Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic

Who this might be right for
HER2-negative Breast CancerHER2-positive Breast CancerRecurrent Breast Cancer+2 more
National Cancer Institute (NCI) 580
Testing effectiveness (Phase 2)Ended earlyNCT03430466
What this trial is testing

Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Kyoto Breast Cancer Research Network 1
Next Page